Barcode Five Rights System



Use Barcode to prevent medication errors



ADERS ® is a barcode point of care, (BPOC), solution

Request Info











Practical Compliance Solutions, Corp. helps care facilities reduce risk at the patient's bedside. Our five rights barcode solution is the easiest to implement. Our barcode point of care system can help prevent medication errors in hospitals, long term care facilities, and assisted living communities.

ADERS ® is our barcode solution for the healthcare industry. It helps eliminate medication errors by allowing caregivers to scan NDC barcodes at the patient's bedside, verifying right patient, right drug, right time, right dose, and right route of administration. For more information click the products menu or send us a web request from our Contact menu. Ask for a DEMO CD. It is the full product that is licensed for an evaluation period.

We are offering a 30 day no-obligation free trial of the ADERS ® software. Care facilities can easily determine if ADERS ® is right for them by using the software as a pilot for a single unit or ward. Click here to download a Microsoft Project plan showing how you can implement a five rights point of care barcode pilot in less than a week. If you Don't own MS Project 2003, then here is a PDF copy just to see.... Download Adobe PDF Data Sheet

View a PowerPoint Presentation of ADERS ®.





Current Patient Safety and Drug Safety Updates from the FDA


FDA Press Releases RSS Feed

FDA Roundup: February 3, 2023
Fri, 03 Feb 2023 17:26:07 EST

  The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

FDA Approves First Oral Treatment for Anemia Caused by Chronic Kidney Disease for Adults on Dialysis
Wed, 01 Feb 2023 18:01:26 EST

  The FDA approved the first oral treatment for anemia caused by chronic kidney disease for adults who have been receiving dialysis for at least four months.

FDA Roundup: January 31, 2023
Tue, 31 Jan 2023 15:52:13 EST

  The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

FDA Proposes Redesign of Human Foods Program to Enhance Coordinated Prevention and Response Activities
Tue, 31 Jan 2023 11:02:16 EST

  FDA Proposes Redesign of Human Foods Program to Enhance Coordinated Prevention and Response Activities

Federal Court Enters Consent Decree Against Florida-based Drug Importer and Distributor
Mon, 30 Jan 2023 16:07:37 EST

  Today, the U.S. District Court for the Southern District of Florida entered a consent decree against LGM Pharma LLC, a drug importer and distributor, for significant CGMP requirement violations.

FDA Proposes Individual Risk Assessment for Blood Donations, While Continuing to Safeguard U.S. Blood Supply
Fri, 27 Jan 2023 08:54:58 EST

  FDA is proposing a change from time-based deferrals to assessing blood donor eligibility using gender-inclusive, individual risk-based questions to reduce the risk of transfusion-transmitted HIV.

FDA Concludes that Existing Regulatory Frameworks for Foods and Supplements are Not Appropriate for Cannabidiol, Will Work with Congress on a New Way Forward
Thu, 26 Jan 2023 10:12:59 EST

  The FDA has concluded that a new regulatory pathway for CBD is needed that balances individuals’ desire for access to CBD products with the regulatory oversight needed to manage risks. The agency is prepared to work with Congress on this matter.

FDA Roundup: January 24, 2023
Tue, 24 Jan 2023 13:37:21 EST

  The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

FDA Announces Action Levels for Lead in Categories of Processed Baby Foods
Tue, 24 Jan 2023 10:28:15 EST

  The FDA is announcing draft guidance for industry on action levels for lead in processed foods that are intended for babies and children under 2 years of age, to help reduce potential health effects in this vulnerable population from dietary exposure to lead.

FDA Denies Marketing of Two Vuse Menthol E-Cigarette Products Following Determination They Do Not Meet Public Health Standard
Tue, 24 Jan 2023 10:21:42 EST

  The FDA issued marketing denial orders for two Vuse menthol e-cigarette products currently marketed by R.J. Reynolds Vapor Company.

FDA Roundup: January 20, 2023
Fri, 20 Jan 2023 17:08:38 EST

  The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

FDA Roundup: January 13, 2023
Fri, 13 Jan 2023 15:24:57 EST

  The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

FDA Roundup: January 10, 2023
Tue, 10 Jan 2023 16:36:48 EST

  The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

FDA Roundup: January 06, 2023
Fri, 06 Jan 2023 15:34:02 EST

  The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

FDA Grants Accelerated Approval for Alzheimer’s Disease Treatment
Fri, 06 Jan 2023 14:07:25 EST

  FDA approved Leqembi (lecanemab-irmb) for treatment of Alzheimer’s disease. Leqembi is the second of a new category of medications approved for Alzheimer’s disease that target the fundamental pathophysiology of the disease.

FDA Roundup: December 30, 2022
Fri, 30 Dec 2022 11:20:01 EST

  The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

FDA Roundup: December 23, 2022
Fri, 23 Dec 2022 11:57:38 EST

  The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

FDA Approves New HIV Drug for Adults with Limited Treatment Options
Thu, 22 Dec 2022 10:35:56 EST

  The FDA approved a new type of antiretroviral medication for adult patients living with HIV-1, whose HIV infections cannot be successfully treated with other available treatments due to resistance, intolerance, or safety considerations.

FDA Roundup: December 20, 2022
Tue, 20 Dec 2022 15:46:18 EST

  The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

Federal Court Enters Consent Decree Against Oklahoma Drug Compounder
Mon, 19 Dec 2022 16:55:00 EST

  Today, the U.S. District Court for the Western District of Oklahoma entered a consent decree against Qualgen LLC, an outsourcing facility with a history of violations.

Food and Drugs Administration--Recalls/Safety Alerts

Daiso Issues Alergy Alert for Prepackaged Snacks
Fri, 03 Feb 2023 20:00:00 EST

  Daiso California LLC of La Mirada, CA is recalling the below listed snacks due of undeclared allergen ingredients.

Fresh Ideation Food Group LLC Recalls Sandwiches and Other Products Because of Possible Health Risk
Fri, 03 Feb 2023 19:00:00 EST

  Fresh Ideation Food Group LLC of Baltimore, MD is recalling products sold from January 24, 2023 through January 30, 2023 because the products have the potential to be contaminated with Listeria monocytogenes

Global Pharma Healthcare Issues Voluntary Nationwide Recall of Artificial Tears Lubricant Eye Drops Due to Possible Contamination
Thu, 02 Feb 2023 17:30:00 EST

  Global Pharma Healthcare is voluntarily recalling all lots within expiry of their Artificial Tears Lubricant Eye Drops, distributed by /EzriCare, LLC- and Delsam Pharma, to the consumer level, due to possible contamination.

Shop Me Ca Recalls “Diep Bao Cream” Because of Possible Health Risk
Wed, 01 Feb 2023 16:40:00 EST

  Shop Me Ca of Herndon, VA is recalling its 10-gram tubes of “Diep Bao Cream” because they have the potential to be contaminated with lead. People with high blood levels of lead may show no symptoms, but the condition may cause damage to the nervous system and internal organs. Acute lead poisoning ma

B&G Foods Issues Voluntary Allergy Alert for Undeclared Peanut in Three Cases of Back to Nature® Fudge Mint Cookies
Wed, 01 Feb 2023 00:00:00 EST

  B&G Foods announced today it is voluntarily recalling three cases (18 individual boxes) of a single date code of 6.4 oz. Back to Nature Fudge Mint Cookies, with a “best by” date of OCT 02 2023, after being notified that an ingredient supplied by a third-party ingredient supplier was contaminated wit

IBSA Pharma Inc. Issues Voluntary Nationwide Recall of Select Lots of TIROSINT®-SOL (levothyroxine sodium) Oral Solution Due to Subpotency
Tue, 31 Jan 2023 00:00:00 EST

  IBSA Pharma Inc. is voluntarily recalling 27 lots of TIROSINT®-SOL (levothyroxine sodium) Oral Solution to the consumer level. This voluntary recall has been initiated because these lots may be subpotent. The company’s analyses show a slight decrease below 95.0% of its labeled amount in levothyroxin

Daiso Issues Allergy Alert on Undeclared Soy in Matsunga Mini Shiruko Sand Biscuits
Mon, 30 Jan 2023 13:41:00 EST

  Daiso California LLC of La Mirada, CA is recalling the below Matsunaga Mini Shiruko Sand Biscuits (sku 4902773016966) due of undeclared soy ingredients. People who have an allergy or severe sensitivity to soy run the risk of serious or life-threatening allergic reaction if they consume this product

Two Rivers Coffee Issues Allergy Alert on Undeclared Peanut Allergen in Peanut Butter Hot Chocolate
Mon, 30 Jan 2023 00:00:00 EST

  Two Rivers Coffee of South Plainfield, NJ is voluntarily recalling its peanut butter single serve hot chocolate pods distributed as "Brooklyn Bean Peanut Butter Cup Hot Cocoa", "Pingo Peanut Butter Cookie Hot Chocolate" and “Cold Stone Peanut Butter Cup Perfection” in 12 count, 40count, and 100 coun

Sovos Brands Intermediate, Inc. Issues Allergy Alert on Undeclared Egg in Rao’s Slow Simmered Soup, Labeled as Chicken & Gnocchi but Containing Vegetable Minestrone
Fri, 27 Jan 2023 08:00:00 EST

  Sovos Brands Intermediate, Inc. (“Sovos”) is voluntarily recalling a limited number of 16-ounce jars of Rao’s Made for Home Slow Simmered Soup, Chicken & Gnocchi, because the affected jars may contain undeclared egg.

Edgewell Personal Care Issues Voluntary Nationwide Recall of Banana Boat Hair & Scalp Sunscreen Due to the Presence of Benzene – UPDATED
Fri, 27 Jan 2023 00:00:00 EST

  Edgewell Personal Care Company (NYSE: EPC) today expanded its voluntary nationwide recall of three batches of Banana Boat Hair & Scalp Sunscreen Spray SPF 30 to the consumer level as outlined in the table below. One additional batch has been added to the original recall announced on July 29, 2022. A

Joy Joy’s Bakery Issues Allergy Alert on Undeclared Wheat in Ube Spanish Bread, Ube Ensaymada, and Ube Roll
Thu, 26 Jan 2023 20:51:00 EST

  January 26, 2023, Joy Joy’s Bakery Lakewood, Washington is recalling Ube Spanish Bread, Ube Ensaymada, and Ube Roll because it may contain undeclared wheat. People who have an allergy or severe sensitivity to wheat run the risk of serious or life-threatening allergic reaction if they consume this p

Snack Innovations Inc. Conducts Voluntary Recall on a Limited Quantity of Drizzilicious Mini Rice Cakes 4oz & .74oz and Popcorn 3.6oz Products in the U.S. Due to Undeclared Peanut Allergen on Packaging
Wed, 25 Jan 2023 18:47:00 EST

  Snack Innovations Inc. of Piscataway, NJ is issuing a voluntary recall on several batches of Drizzilicious branded mini rice cake bites, and drizzled popcorn products with the lot numbers listed below due to an undeclared peanut residue. People who have an allergy or severe sensitivity to peanuts ru

Almondy is Initiating a Recall of a Limited Quantity of Almondy Chocolate Cake with Daim 14.1oz
Wed, 25 Jan 2023 17:48:00 EST

  Almondy is initiating a recall of a limited quantity Almondy Chocolate cake with Daim 14.1oz as a metal object has been found in a cake. The products are being recalled as a precautionary measure.

Corim Industries Issues Allergy Alert on Undeclared Peanuts in Peanut Butter Hot Chocolate
Mon, 23 Jan 2023 00:00:00 EST

  Corim Industries, USA of Brick, New Jersey is voluntarily recalling the following peanut butter hot chocolate products because they may contain undeclared peanut. People who have allergies to peanuts run the risk of serious or life-threatening allergic reaction if they consume the following products

SkinnyDipped® Issues Allergy Alert on Undeclared Peanuts in a Limited Number of SkinnyDipped® Dark Chocolate Nut Products
Fri, 20 Jan 2023 13:01:00 EST

  January 20, 2023, SkinnyDipped® of Seattle, WA is voluntarily recalling a limited quantity of SkinnyDipped® Dark Chocolate Cocoa Almond 3.5oz and SkinnyDipped® Dark Chocolate Salted Caramel Cashew 3.5oz due to an undeclared peanut allergen in an ingredient from a raw material supplier. People who ha

Fullei Fresh Issues Correction on Alfalfa Sprout Recall Because of Possible Health Risk
Thu, 19 Jan 2023 12:45:00 EST

  Fullei Fresh is voluntarily recalling Alfalfa Sprouts due to the detection of Shiga toxin producing E.coli (STEC.) Shiga toxin producing E.coli is an organism that can cause foodborne illness in a person who eats a food item contaminated with it. Symptoms of infection may include stomach cramps, dia

Utopia Foods Expands Recall on “Enoki Mushrooms” Because of Possible Health Risk
Fri, 13 Jan 2023 19:30:00 EST

  Utopia Foods Inc is expanding the recall of its 200g packages of “Enoki Mushrooms”, imported from China, with clear markings of “Best before 03/02/2023” or “Best before 03.09.23” distributed between 01/06 to 01/13, 2023 have the potential to be contaminated with Listeria monocytogenes

Ameripack Foods LLC Announces Allergy Alert for Undeclared Soy and Egg in H-E-B Meal Simple Chocolate Chunk Brownie
Wed, 11 Jan 2023 00:00:00 EST

  Ameripack Foods LLC of Hughes Springs, TX is issuing a recall for 976lbs. of brownies for H-E-B Meal Simple Chocolate Chunk Brownie 13 Oz due to an undeclared – Soy & Egg. People who have an allergy or severe sensitivity to soy or egg run the risk of serious or life-threatening allergic reaction if

Daiso Issues Allergy Alert Tohato and Kashiwado Snacks
Tue, 10 Jan 2023 20:30:00 EST

  Daiso California LLC of La Mirada, CA is recalling the below listed Tohato and Kashiwado snacks due of undeclared allergen ingredients.

Spectrum Laboratory Products, Inc. Issues Voluntary Worldwide Recall of Epinephrine (L-Adrenaline) USP Bulk Active Pharmaceutical Ingredient (API) Due to Discoloration of Product
Mon, 09 Jan 2023 20:30:00 EST

  Spectrum Laboratory Products, Inc. is voluntarily recalling three lots of Epinephrine (L-Adrenaline) USP, a bulk active pharmaceutical ingredient (API) used to manufacture or compound prescription products, to the user level. Customer complaints have found the product to be discolored.

What's New: Drugs RSS Feed

Study Data Standards Resources
Fri, 03 Feb 2023 18:17:35 EST

  Study Data Standards Resources

Antimicrobial Resistance Information from FDA
Fri, 03 Feb 2023 17:17:34 EST

  Antimicrobial resistance (AMR)—the ability of a microorganism (bacteria, virus, fungi, parasite) to resist the effects of a drug—is a serious, complex and costly public health problem. Learn what FDA is doing to address AMR.

Endocrinologic and Metabolic Drugs Advisory Committee Roster
Fri, 03 Feb 2023 16:28:37 EST

  Advisory Committees (Drugs)

What's New Related to Drugs
Fri, 03 Feb 2023 16:16:29 EST

  Want to know what's new on drugs from FDA? This page provides quick links to the latest on a variety of topics including: drug approvals, safety warnings, drug shortages, etc.

GDUFA III Controlled Correspondence Enhancements
Fri, 03 Feb 2023 16:08:03 EST

  Controlled correspondence is a correspondence submitted to FDA by or on behalf of a generic drug manufacturer or related industry requesting information on a specific element of generic drug product development or concerning certain post-approval submission requirements.

A Deep Dive: FDA Draft Guidance on Statistical Approaches to Establishing Bioequivalence - 03/14/2023
Fri, 03 Feb 2023 16:05:46 EST

  Webinar will take a deeper look into the draft guidance for new and revised content and provide clarification to comments received through the public docket.

FDA/CRCG Considerations for and Alternatives to Comparative Clinical Endpoint and Pharmacodynamic Bioequivalence Studies for Generic Orally Inhaled Drug Products - 04/20/2023
Fri, 03 Feb 2023 15:12:03 EST

  FDA recommendations for establishing bioequivalence (BE) with local drug delivery for orally inhaled drug products (OIDPs) often involve study designs for conducting comparative clinical endpoint (CCEP) and pharmacodynamic (PD) BE studies.

Electronic Registration and Listing Compliance Program
Fri, 03 Feb 2023 14:51:04 EST

  Establishment registration and drug listing data is submitted by drug manufacturers and own label drug distributors through electronic means using Structured Product Labeling format (SPL).

US-Canada Regional ICH Consultation - 05/11/2022
Fri, 03 Feb 2023 14:16:55 EST

  FDA and Health Canada will be co-hosting a regional public meeting to provide information and solicit input prior to the next ICH biannual Assembly and Management Committee meetings scheduled for May 21 - 25, 2022.

User Fee Lists
Fri, 03 Feb 2023 13:20:17 EST

  Fiscal Year (FY) 2017 GDUFA facility fees are due on October 3, 2016.

Timeline of Selected FDA Activities and Significant Events Addressing Substance Use and Overdose Prevention
Fri, 03 Feb 2023 13:19:48 EST

  Timeline of Selected FDA Activities and Significant Events Addressing Opioid Misuse and Abuse

Generic Drug Facilities, Sites and Organization Lists
Fri, 03 Feb 2023 13:16:25 EST

  Generic Drug Facilities, Sites and Organization Lists

CDER Scientific Review Documents Supporting Emergency Use Authorizations for Drug and Biological Therapeutic Products | COVID-19
Fri, 03 Feb 2023 11:59:33 EST

  CDER Scientific Reviews Supporting EUA for Therapeutic Products

OTC Drug Review Process | OTC Drug Monographs
Fri, 03 Feb 2023 11:56:47 EST

  The Over-the-Counter (OTC) Drug Review was established to evaluate the safety and effectiveness of OTC drug products marketed in the United States before May 11, 1972.

Over-the-Counter (OTC) Drug Review | OTC Monograph Reform in the CARES Act
Fri, 03 Feb 2023 11:54:50 EST

  Information about Over-the-Counter (OTC) Monograph Reform

Oncology (Cancer) / Hematologic Malignancies Approval Notifications
Fri, 03 Feb 2023 11:51:29 EST

  Oncology (Cancer) / Hematologic Malignancies Approval Notifications

Regulatory Science in Action
Fri, 03 Feb 2023 11:38:42 EST

  Developing new tools, standards, and approaches to assess drug safety, efficacy, quality, and performance

Drugs
Fri, 03 Feb 2023 11:02:44 EST

  Consumer articles about over-the-counter and prescription drugs.

Generic Drugs Program Activities Report - FY 2022 Monthly Performance
Fri, 03 Feb 2023 10:56:44 EST

  This report provides monthly activities metrics for the FDA Generic Drugs Program, outlining agency actions on abbreviated new drug applications. Data includes approvals, applications received, complete responses, and more.

Drug Shortages | Additional News and Information
Fri, 03 Feb 2023 09:37:38 EST

  Drug Shortages: Additional News and Information

Whats New Vaccines Blood Biologics RSS Feed

Antimicrobial Resistance Information from FDA
Fri, 03 Feb 2023 17:17:34 EST

  Antimicrobial resistance (AMR)—the ability of a microorganism (bacteria, virus, fungi, parasite) to resist the effects of a drug—is a serious, complex and costly public health problem. Learn what FDA is doing to address AMR.

FluMist Quadrivalent
Fri, 03 Feb 2023 16:17:52 EST

  For active immunization of individuals 2 through 49 years of age for the prevention of influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine.

Gardasil
Fri, 03 Feb 2023 16:02:08 EST

  Product approval information for Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine, Recombinant also known as Gardasil.

Questions about Tissues
Fri, 03 Feb 2023 15:40:03 EST

  Information about tissues, questions and answers, donor screening and testing, donor eligibility

Biologics PREA Reviews and Labeling Changes
Fri, 03 Feb 2023 15:26:28 EST

  PREA Labeling Changes, Medical, Statistical, and Clinical Pharmacology Reviews of Pediatric Studies Conducted under Section 505B of the Federal Food, Drug, and Cosmetic Act (the Act), as amended by the FDA Amendments Act of 2007 (FDAAA). These assessments are for CBER regulated drugs approved under section 505 of the Act and biological drugs licensed under section 351 of the Public Health Service Act.

ODACTRA
Fri, 03 Feb 2023 15:11:44 EST

  Product approval information for use in adults 18 through 65 years of age as immunotherapy for house dust mite- (HDM)-induced allergic rhinitis, with or without conjunctivitis, confirmed by in vitro testing for IgE antibodies to Dermatophagoides farinae or Dermatophagoides pteronyssinus house dust mites, or skin testing to licensed house dust mite allergen extracts.

Safety & Availability (Biologics)
Fri, 03 Feb 2023 15:09:56 EST

  Important information about the safety and availability of biological products.

Workshops, Meetings & Conferences (Biologics)
Fri, 03 Feb 2023 14:55:28 EST

  Information on CBER sponsored or co-sponsored meetings, conferences and workshops about various biologics in order to educate the public and seek the opinion of interested parties.

What’s New for Biologics
Fri, 03 Feb 2023 14:49:41 EST

  Latest news from the Center for Biologics Evaluation and Research

CDER Scientific Review Documents Supporting Emergency Use Authorizations for Drug and Biological Therapeutic Products | COVID-19
Fri, 03 Feb 2023 11:59:33 EST

  CDER Scientific Reviews Supporting EUA for Therapeutic Products

FDA Clinical Trial Requirements, Regulations, Compliance, and GCP Conference - 03/21/2023
Fri, 03 Feb 2023 09:04:12 EST

  This two-day conference is intended to share information among FDA representatives and the regulated community, to facilitate the understanding of regulations, guidelines and practices, and to suggest methods and opportunities to enhance the research professional’s product development experience.

FDA Clinical Trial Requirements, Regulations, Compliance, and GCP Conference - 06/13/2023
Fri, 03 Feb 2023 09:04:11 EST

  This three-day virtual conference is intended to share information among FDA representatives and the regulated community to facilitate the understanding of regulations, guidelines and practices, and to suggest methods and opportunities to enhance the research professional’s product development experience.

Jobs at the Center for Biologics Evaluation and Research (CBER)
Thu, 02 Feb 2023 16:26:52 EST

  CBER has unique opportunities for individuals with backgrounds in science or administration to fill positions involved in the regulation and research of blood, vaccines and therapeutics.

2023 Meeting Materials, Vaccines and Related Biological Products Advisory Committee
Thu, 02 Feb 2023 11:24:21 EST

  This is the main page for the CBER 2023 Meeting Materials, Vaccines and Related Biological Products Advisory Committee (VRBPAC).

Charter of the Cellular, Tissue and Gene Therapies Advisory Committee
Thu, 02 Feb 2023 10:23:04 EST

  This is the charter for CBER's Cellular, Tissue and Gene Therapies Advisory Committee.

MedWatch Forms for FDA Safety Reporting
Thu, 02 Feb 2023 09:56:01 EST

  Safety reporting portal for health professionals, patients, consumers and industry. Find pdf fillable forms in English and Spanish and a link to report safety concerns to the FDA online.

Recently Issued Guidance Documents
Wed, 01 Feb 2023 15:19:25 EST

  This page lists Recently Issued CBER and Cross-Center Guidance Documents.

Administrative Guidances
Wed, 01 Feb 2023 15:18:53 EST

  This page lists Administrative Guidance documents.

Study Data Technical Conformance Guide - Technical Specifications Document
Wed, 01 Feb 2023 12:22:17 EST

  This technical specifications document represents the Food and Drug Administration's (FDA's) current thinking on this topic.

Patient Listening Session Summaries
Wed, 01 Feb 2023 11:05:15 EST

  Patient Listening Session summaries are published after each session to share a high-level summary of the discussion. The Office of Patient Affairs draft summaries for FDA-requested sessions and the patient community requester drafts summaries for Patient-led sessions.





See how to prevent medication errors with bar codes using ADERS. Get your free pilot started today.






Products



 
 

Services




Contact Us


About PCS


Corporate Headquarters


Practical Compliance Solutions
One Orient Way
Suite F156
Rutherford, NJ 07070
  201-728-8809


40.827731 N 74.101029 W

Connect With Us

   
 
 
© 2002 - 2023 - Copyright Practical Compliance Solutions - All rights reserved